Conbo Medical-B (02216) released its interim results for the six months ending June 30, 2024, during which the group achieved...
According to the Wise Financial News APP, Conbo Medical-B (02216) released its interim results for the six months ending June 30, 2024, with the group generating revenue of 3.704 million US dollars, a 29% year-on-year decrease; research and development costs of 6.491 million US dollars, a 37% year-on-year decrease; net loss attributable to owners of the parent company of 7.943 million US dollars, a 46.08% year-on-year decrease; loss per share of 0.02 US dollars.
In the first half of 2024, with the localization transfer of the manufacturing process for InterVapor thermal vapor treatment system and navigation products, the company effectively reduced product production costs, leading to a gross margin increase to 80%. At the same time, the company focuses on the research and commercialization of core products, optimizing expenses through various measures, resulting in a significant narrowing of net losses by 46% year-on-year.
